Vertex Pharmaceuticals — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Vertex is a global biotechnology company whose current product revenue is primarily from cystic fibrosis (CF) medicines. Financial amounts below are in U.S. dollars; income and cash-flow comparisons are year over year.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Product revenue | $2,483.5 million (+6%) | $2,334.3 million | $7,351.5 million (+11%) | $6,628.0 million |
| Operating income | $1,038.1 million (-8%) | $1,126.7 million | $2,843.5 million (-13%) | $3,273.9 million |
| Net income | $1,035.3 million (+11%) | $930.5 million | $2,650.8 million (+6%) | $2,503.1 million |
| Diluted EPS | $3.97 | $3.59 | $10.18 | $9.68 |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $3,302.7 million | $3,051.5 million |
Q3 operating margin was approximately 41.8%, versus 48.3% a year earlier; nine-month operating margin was approximately 38.7%, versus 49.4%. Cost of sales was 13% of revenue in Q3 2023 versus 12% in Q3 2022, and 12% for both nine-month periods. The filing does not report EBITDA.
TRIKAFTA/KAFTRIO generated $2,274.3 million in Q3 revenue (+13%) and $6,611.4 million for nine months (+17%). Other CF products declined; management attributed this mainly to patients switching to TRIKAFTA/KAFTRIO. Nine-month U.S. revenue rose 5%, while ex-U.S. revenue rose 21%.
Liquidity, cash flow and obligations
- Cash, cash equivalents and marketable securities totaled $13.63 billion at September 30, 2023, up from $10.89 billion at December 31, 2022. Working capital was $11.10 billion.
- Nine-month investing cash outflow was $2.26 billion, primarily reflecting net purchases of marketable securities; financing cash outflow was $442.4 million, including share repurchases and employee stock-plan payments. Cash, cash equivalents and restricted cash increased $604.6 million.
- The balance sheet reported $390.3 million of long-term finance lease liabilities and $354.4 million of long-term operating lease liabilities. The $500 million revolving credit facility was undrawn; no conventional borrowing balance is reported. The company was in covenant compliance.
- Management said existing liquidity and expected product-sales cash flows should fund operations for at least the next 12 months.
Changes, outlook and notable items
- Revenue growth was led by TRIKAFTA/KAFTRIO uptake, including younger patients and ex-U.S. markets with new reimbursements or label expansions. Meanwhile, total costs and expenses increased 20% in Q3 and 34% for nine months.
- R&D expense rose 26% in Q3 and 27% for nine months, principally from advancing clinical trials and drug supply for pain, exa-cel and type 1 diabetes programs. Acquired in-process R&D (AIPR&D) was $509.3 million for nine months, versus $92.9 million, including Entrada payments, $170 million paid to CRISPR, and the $47.5 million Septerna program acquisition. These charges contributed to lower operating income.
- Interest income increased substantially to $167.9 million in Q3 and $435.2 million for nine months, primarily due to higher market rates and larger cash and securities balances. The nine-month effective tax rate was 18.0%, compared with 20.7%, partly reflecting an R&D tax-credit study benefit and excess stock-compensation tax benefits.
- Management reported exa-cel applications under review in the U.S., E.U. and U.K.; FDA action dates were December 8, 2023 for sickle cell disease and March 30, 2024 for transfusion-dependent beta thalassemia. The filing anticipated decisions in the coming months. It expected vanzacaftor trial results and acute-pain VX-548 trial results in early 2024; these are expectations, not guarantees. No specific full-year revenue or earnings guidance is provided in the supplied filing text.
- In November 2023, Vertex determined that additional preclinical studies of the DMD gene-editing delivery system were needed; any effect on the $127.7 million contingent-consideration liability was to be recognized at year-end. Vertex also discontinued VX-864 development after non-serious rash events in some patients.
- Key risks include clinical and regulatory uncertainty, reimbursement and market access, manufacturing and supply-chain execution, and volatility in strategic equity investment values. The company reported no material legal proceedings and no material changes to the risk factors in its 2022 Form 10-K.
Investor verification priorities
- Track TRIKAFTA/KAFTRIO growth, payer reimbursement and the pace of patient transitions from older CF products.
- Check exa-cel regulatory decisions, launch readiness, treatment capacity and commercial adoption against the stated review timelines.
- Assess whether rising R&D and AIPR&D spending translates into clinical progress, and monitor the DMD program and contingent-consideration remeasurement.
- Review subsequent cash flows, investment maturities, share repurchases and liquidity; $2.7 billion remained authorized under the repurchase program at September 30, 2023.
- Confirm future tax-rate trends and the impact of interest rates, equity investment volatility, reimbursement changes and product concentration on results.